Cytomx Thera (CTMX) |
|
8.155 0.105 (1.3%)
|
06-04 16:00 |
|
Open: |
8.02 |
Pre. Close: |
8.05 |
|
High:
|
8.6599 |
Low:
|
8.01 |
|
Volume:
|
745,431 |
Market Cap:
|
375M |
|
|
|
|
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.668 - 8.71 |
8.71 - 8.746 |
|
Low:
|
7.915 - 7.961 |
7.961 - 8 |
|
Close:
|
8.081 - 8.152 |
8.152 - 8.214 |
|
Technical analysis |
as of: 2020-06-04 4:30:07 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 14.61 One year: 18.02 |
| Support: |
Support1: 7.78 Support2: 6.47 |
| Resistance: |
Resistance1: 12.51 Resistance2: 15.43 |
| Pivot: |
8.86  |
| Moving Average: |
MA(5): 8.25 MA(20): 10.15
MA(100): 8.13 MA(250): 8.36 |
| MACD: |
MACD(12,26): -0.53 Signal(9): -0.22 |
| Stochastic oscillator: |
%K(14,3): 6.21 %D(3): 4.42 |
| RSI: |
RSI(14): 38.48 |
| 52-week: |
High: 15.43 Low: 3.60 Change(%): -21.5 |
| Average Vol(K): |
3-Month: 64845 10-Days: 72783 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.CTMX has closed above bottom band by 14.3%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to CTMX's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 08 May 2020
CytomX Therapeutics, Inc. (CTMX) Q1 2020 Earnings Call Transcript - Motley Fool
Thu, 21 May 2020
Pomerantz Law Firm Announces the Filing of a Class Action against CytomX Therapeutics Inc. and Certain Officers – CTMX - GlobeNewswire
Wed, 03 Jun 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytomX Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline – CTMX - Yahoo Finance
Mon, 18 May 2020
CytomX Slumps On Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha
Wed, 03 Jun 2020
Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Conn's, Elanco Animal Health, Ryder System, and CytomX and Encourages Investors to Contact the Firm - GlobeNewswire
Fri, 29 May 2020
CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
46 |
| Shares Float (M) |
37 |
|
% Held by Insiders
|
2.30 |
|
% Held by Institutions
|
84.32 |
|
Shares Short (K)
|
1,070 |
|
Shares Short P. Month (K)
|
864 |
Stock Financials |
|
EPS
|
-1.670 |
|
EPS Est This Year
|
-1.490 |
|
EPS Est Next Year
|
-1.410 |
|
Book Value (p.s.)
|
1.520 |
|
Profit Margin
|
-97.82 |
|
Operating Margin
|
-125.16 |
|
Return on Assets (ttm)
|
-13.8 |
|
Return on Equity (ttm)
|
-78.9 |
|
Qtrly Rev. Growth
|
68.2 |
|
Gross Profit (p.s.)
|
1.252 |
|
Sales Per Share
|
1.690 |
|
EBITDA (p.s.)
|
-2.059 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-151 |
|
Levered Free Cash Flow (M)
|
-177 |
Stock Valuations |
|
PE Ratio
|
-4.88 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.37 |
|
Price to Sales
|
4.82 |
|
Price to Cash Flow
|
-2.48 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
